AI-Powered Autism Research

Autism spectrum disorder encompasses a range of neurodevelopmental conditions. AI agents research gut-brain interventions, social cognition enhancers, and sensory processing therapies.

Standard of Care

Behavioral interventions (ABA, ESDM for early intervention), speech/language therapy, occupational therapy, social skills training. Medications for comorbidities: risperidone/aripiprazole (irritability), SSRIs (anxiety), stimulants (ADHD).

Prevalence

~1 in 36 children (~5.4 million Americans). 4× more common in males. Prevalence increasing — likely due to broader diagnostic criteria and awareness.

Key Biomarkers

• ADOS-2 assessment
• Eye-tracking patterns
• EEG connectivity patterns
• Gut microbiome composition
• Metabolomic profiles (amino acids, SCFAs)

Emerging Research

Microbiome transfer therapy (MTT) showing sustained improvement in ASD symptoms (Kang et al., Arizona State). Suramin (purinergic signaling modulator) in Phase 2 trials. Oxytocin nasal spray for social cognition. Bumetanide (shifting GABA from excitatory to inhibitory). Precision medicine based on genetic/metabolic subtypes.

Frequently Asked Questions

How does the gut microbiome relate to autism?

~70% of autistic individuals have GI symptoms. ASD patients show distinct microbiome profiles — reduced Prevotella, Bifidobacterium, and Desulfovibrio. Microbiome Transfer Therapy (MTT) improved GI and behavioral symptoms by 45% in a clinical trial, with benefits persisting 2 years later. The gut-brain axis is a major research focus.

What is suramin for autism?

Suramin blocks purinergic signaling (P2X/P2Y receptors), which may be hyperactivated in ASD. A small Phase 2 trial showed improved social communication and reduced restricted behaviors after a single IV dose. Larger trials are underway. The 'cell danger response' theory underpins this approach.